Will Biobeat’s wearable BP patch become the new standard in hypertension diagnosis?
Biobeat raises $50M to commercialize its FDA-cleared patch-worn ABPM system. Find out how this device could change hypertension care in the U.S.
Biobeat raises $50M to commercialize its FDA-cleared patch-worn ABPM system. Find out how this device could change hypertension care in the U.S.